JAMA Neurology-脑外伤后,一年内功能恢复状况如何?

2021-07-23 Freeman MedSci原创

脑损伤后,一年内功能恢复状况如何?

创伤性脑损伤(TBI)是美国和全球死亡和残疾的一个主要原因。中度至重度TBI(msTBI)的幸存者在返回工作或学校、社会关系和正常日常生活活动方面通常会遇到长期的挑战。从长远来看,MSTBI还与健康状况不佳、认知能力下降、神经退行性疾病和整个生命期对个人护理的需求增加的风险有关。

然而,长期随访研究报告称,MSTBI后的恢复和残余残疾的程度有相当大的差异。虽然中度TBI(格拉斯哥昏迷量表[GCS]9-12分)和重度TBI(GCS 3-8分)都会产生终身损伤,但一些长期结果研究表明,即使在重度TBI后,多达20%的幸存者会在受伤后5年内恢复功能独立。一些研究描述了MSTBI患者的长期结果,但很少有研究涉及早期评估或对患者进行纵向随访,以跟踪从急性期到慢性期的康复结果。捕捉毫秒级创伤后的全部纵向结果轨迹对确定短期和长期变量至关重要,这些变量将区分那些将继续有利恢复的患者和那些长期结果不佳的高风险患者。这反过来又为减少与msTBI相关的整体残疾的干预措施提供了参考。

"TBI研究与临床知识转化"(TRACK-TBI)研究是美国最大的前瞻性观察研究,全面调查TBI后从急性期(例如,入院)到慢性期(例如,受伤后12个月)的自然恢复历史。

藉此, 美国威斯康辛大学的Michael A. McCrea等人利用此队列,探究了受伤后早期(即2周)和受伤后3、6和12个月的功能结果的系统监测。旨在扩展现有的知识。


在TRACK-TBI研究的2679人中,总共有484名符合条件的患者被纳入。重度TBI(n = 362;283名男性);中度TBI(n = 122;98名男性)。

在受伤后2周,290名严重创伤性疾病参与者中的36人(12.4%)和93名中度创伤性疾病参与者中的38人(41%)有良好的结果(GOSE评分4-8);严重创伤性疾病组322人中的301人(93.5%)和中度创伤性疾病组103人中的81人(78.6%)在DRS上有中度残疾或更差(总评分≥4)。

到受伤后12个月,271名重度TBI患者中的142人(52.4%)和72名中度TBI患者中的54人(75%)取得了良好的结果。

近五分之一的重度TBI患者(270人中的52人[19.3%])和三分之一的中度TBI患者(71人中的23人[32%])在12个月时报告没有残疾(DRS得分0)。

在2周时处于植物状态的参与者中,79人中有62人(78%)恢复了意识,56人中有14人(25%)在12个月前恢复了方向感。

这个研究的重要意义在于发现了:msTBI患者在受伤后2周至12个月内经常表现出主要的功能获益,包括恢复独立。短期内的严重损伤并不预示着相当多的msTBI患者会出现不良后果。当讨论受伤后头2周的预后时,临床医生应特别谨慎地做出早期的、明确的预后声明,暗示msTBI患者的预后不佳和撤销维持生命的治疗。

原文出处;
McCrea MA, Giacino JT, Barber J, Temkin NR, Nelson LD, Levin HS, Dikmen S, Stein M, Bodien YG, Boase K, Taylor SR, Vassar M, Mukherjee P, Robertson C, Diaz-Arrastia R, Okonkwo DO, Markowitz AJ, Manley GT; TRACK-TBI Investigators, Adeoye O, Badjatia N, Bullock MR, Chesnut R, Corrigan JD, Crawford K, Duhaime AC, Ellenbogen R, Feeser VR, Ferguson AR, Foreman B, Gardner R, Gaudette E, Goldman D, Gonzalez L, Gopinath S, Gullapalli R, Hemphill JC, Hotz G, Jain S, Keene CD, Korley FK, Kramer J, Kreitzer N, Lindsell C, Machamer J, Madden C, Martin A, McAllister T, Merchant R, Ngwenya LB, Noel F, Nolan A, Palacios E, Perl D, Puccio A, Rabinowitz M, Rosand J, Sander A, Satris G, Schnyer D, Seabury S, Sherer M, Toga A, Valadka A, Wang K, Yue JK, Yuh E, Zafonte R. Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study. JAMA Neurol. 2021 Jul 6:e212043. doi: 10.1001/jamaneurol.2021.2043. Epub ahead of print. PMID: 34228047; PMCID: PMC8261688.

 
 
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2001422, encodeId=e8a9200142254, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 26 00:59:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599350, encodeId=55861599350b2, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Jul 24 20:59:13 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001962, encodeId=f42d1001962ad, content=真好,学习了,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Fri Jul 23 11:26:49 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001925, encodeId=ceee10019258e, content=学习一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jul 23 09:35:54 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036753, encodeId=694b1036e5313, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jul 23 08:59:13 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
    2021-07-26 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2001422, encodeId=e8a9200142254, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 26 00:59:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599350, encodeId=55861599350b2, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Jul 24 20:59:13 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001962, encodeId=f42d1001962ad, content=真好,学习了,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Fri Jul 23 11:26:49 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001925, encodeId=ceee10019258e, content=学习一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jul 23 09:35:54 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036753, encodeId=694b1036e5313, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jul 23 08:59:13 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
    2021-07-24 mnda
  3. [GetPortalCommentsPageByObjectIdResponse(id=2001422, encodeId=e8a9200142254, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 26 00:59:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599350, encodeId=55861599350b2, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Jul 24 20:59:13 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001962, encodeId=f42d1001962ad, content=真好,学习了,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Fri Jul 23 11:26:49 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001925, encodeId=ceee10019258e, content=学习一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jul 23 09:35:54 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036753, encodeId=694b1036e5313, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jul 23 08:59:13 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
    2021-07-23 智慧药

    真好,学习了,感谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2001422, encodeId=e8a9200142254, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 26 00:59:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599350, encodeId=55861599350b2, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Jul 24 20:59:13 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001962, encodeId=f42d1001962ad, content=真好,学习了,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Fri Jul 23 11:26:49 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001925, encodeId=ceee10019258e, content=学习一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jul 23 09:35:54 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036753, encodeId=694b1036e5313, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jul 23 08:59:13 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
    2021-07-23 学医无涯

    学习一下~

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2001422, encodeId=e8a9200142254, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 26 00:59:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599350, encodeId=55861599350b2, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Jul 24 20:59:13 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001962, encodeId=f42d1001962ad, content=真好,学习了,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Fri Jul 23 11:26:49 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001925, encodeId=ceee10019258e, content=学习一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jul 23 09:35:54 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036753, encodeId=694b1036e5313, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Jul 23 08:59:13 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
    2021-07-23 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Brain:丹麦百万人研究:多次脑外伤后,癫痫风险更高!

Brain:丹麦百万人研究:多次脑外伤后,癫痫风险更高!

J Neurol Neurosur Ps:脑外伤患者精神药物和止痛药使用情况分析

颅脑损伤后使用精神药物和止痛药物的比例较高,建议定期进行医学随访并总结这些药物使用情况。

脑外伤患者脱水剂、甘露醇和浓盐的使用情况?

《梅斯直播课:颅脑创伤临床救治及影像资料》——刘佰运

脑外伤患者常规抗癫痫时长

脑外伤患者常规抗癫痫一个周吗?